Friday 17 April 2020
Here is our summary of the day's hottest RNS alerts from across London's Alternative Investments Market (AIM).
Gfinity Plc (GFIN.L)
Gfinity selected to deliver The eCricket Challenge
Gfinity plc, a world-leading esports and gaming solutions provider, announces it has been selected by premier cricket broadcaster Willow TV (owned by the Times Group) to design and deliver "The eCricket Challenge", in partnership with Betway. "The eCricket Challenge" is a TV series that will see some of the biggest names in world cricket competing against each other in the video game Cricket 19.
Gfinity designed and developed "The eCricket Challenge" format where players compete remotely in five-over matches. Through leveraging Gfinity's virtual gaming expertise, cricket superstars from across three continents, were connected for real-time live games. The pre-recorded shows, hosted from the Gfinity Esports Arena in Fulham, London will premiere in the U.S. and Canada, with new episodes every Sunday starting on 19 April 2020.
"The eCricket Challenge" features global superstars including Jofra Archer, Stuart Broad and Liam Plunkett representing England, Kieron Pollard, Jason Holder, and Andre Fletcher joining from West Indies and Glenn Maxwell playing for Australia.
Hutchison China Meditech Ltd (HCM.L)
Chi-Med Announces Surufatinib Granted U.S. FDA Fast Track Designations for the Treatment of Both Pancreatic and Non-Pancreatic Neuroendocrine Tumors
Hutchison China MediTech Limited announced that the U.S. Food and Drug Administration ("FDA") has granted two Fast Track Designations for the development of surufatinib, for the treatment of both advanced and progressive pancreatic neuroendocrine tumors ("NET") and extra-pancreatic (non-pancreatic) NET in patients who are not amenable for surgery.
The FDA Fast Track Designation is one of several approaches utilized by the U.S. FDA to expedite development and review of potential medicines for serious conditions and that fulfill unmet medical needs. A potential new medicine may fill an unmet medical need by being the first therapy to address a specific serious condition, offer clinically significant advantages over available therapies, act via a different mechanism of action than available therapies, or have a benefit in patients who are unresponsive to or intolerant of available therapies. Programs that receive Fast Track Designation are entitled to more frequent interactions with the U.S. FDA on drug development plan, as well as eligibility for accelerated approval, priority review, and rolling review.
Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with vascular endothelial growth factor receptor ("VEGFR") and fibroblast growth factor receptor (FGFR), which both inhibit angiogenesis, and colony stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated macrophages, promoting the body's immune response against tumor cells. Its unique dual mechanism of action may be very suitable for possible combinations with other immunotherapies.
Chi-Med currently retains all rights to surufatinib worldwide.
Angle Plc (AGL.L)
Parsortix performance in head and neck cancer
ANGLE plc, a world-leading liquid biopsy company, announced that the University of Athens has published results of new work undertaken in head and neck squamous cell carcinoma (HNSCC) demonstrating the use of ANGLE's Parsortix®system in the analysis of gene expression and epigenetic alterations (DNA methylation markers) on circulating tumor cells (CTCs) from a simple blood test.
Head and neck cancer is the sixth most common cancer in the world accounting for more than 550,000 occurrences and 300,000 deaths each year, and the 5-year overall survival rate is extremely low at 40% to 50%1. HNSCC is a devastating disease and novel treatments are urgently needed. The researchers believe that "molecular characterization of CTCs can be a powerful prognostic tool while serial assessments of CTCs at different time points during treatment may guide treatment decisions".
To assess the potential for molecular characterisation of CTCs enriched by Parsortix, the researchers undertook a direct comparison of Parsortix using identical blood draws with an antibody-based approach to CTC capture for 50 HNSCC patients and 18 healthy volunteers. The results demonstrated that the Parsortix system had key advantages including:
much higher CTC harvesting positivity rates;
higher purity samples with lower levels of non-specific contaminant cells;
excellent RNA quality for molecular analysis;
higher relative expression levels for key cancer genes, including PDL1, which is a key target for immunotherapy drugs especially in this type of cancer;
significantly higher proportion of samples testing positive for epigenetic alterations in CTCs (DNA methylation markers), which is a key area for cancer investigation.
The research has been published as a peer-reviewed publication in the Nature Scientific Reports and may be accessed via https://angleplc.com/library/publications/ .